Aging Research Exposed: IL-11 vs. Telomir - Science or Hype?

In today’s video, we’re taking a closer look at two very different aging breakthroughs that have been making headlines. One of them seems like a major scientific breakthrough, while the other has some people wondering if it’s just a pump to boost stock prices. 🧐

First, we examine the legit-sounding research on Interleukin 11 (IL-11), where scientists are knocking out this protein to reduce inflammation and slow aging. This therapy has the potential to revolutionize how we age by targeting the root cause of tissue damage and aging-related disease. But is it too good to be true?

Then, we turn to Telomir Pharmaceuticals, a company claiming to extend lifespan by lengthening telomeres—the DNA endcaps that shorten as we age. While telomeres play a role in aging, we’ll look deeper to see if this company’s bold claims hold up, or if it’s just another stock pump hyping up the next "miracle cure."

In this video, we’ll dig into how you can critically evaluate news stories on scientific breakthroughs, separating legitimate advancements from flashy headlines meant to pump stocks. ⚖️

Is Telomir a game-changer, or just a speculative play?
Can IL-11 therapy really slow aging?

Let’s get to the bottom of these claims together! 🔍

Don’t forget to hit like and subscribe for more insights on science, tech, and how to cut through the hype in today’s news.

JOIN LSN Patreon for exclusive access to news, tips and a community of like minded longevity enthusiasts: https://www.patreon.com/user?u=29506604

#AgingScience #Longevity #IL11 #Telomeres #TelomirPharmaceuticals #AntiAging #StockPump #Biotech #Interleukin11 #CriticalThinking